182 related articles for article (PubMed ID: 25783515)
1. Total lesion glycolysis determined per RECIST 1.1 criteria predicts survival in EGFR mutation-negative patients with advanced lung adenocarcinoma.
Ho TY; Chou PC; Yang CT; Tsang NM; Yen TC
Clin Nucl Med; 2015 Jun; 40(6):e295-9. PubMed ID: 25783515
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.
Wang D; Zhang M; Gao X; Yu L
PLoS One; 2016; 11(6):e0158307. PubMed ID: 27336755
[TBL] [Abstract][Full Text] [Related]
3. [Evaluate the value of (18)F-FDG PET-CT imaging in predicting the mutationsin epidermal growth factor receptor in lung adenocarcinoma].
Ding CY; Yang WP; Guo Z; Sun J; Li YY; Li TR
Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):528-531. PubMed ID: 28728300
[No Abstract] [Full Text] [Related]
4. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.
Chung HW; Lee KY; Kim HJ; Kim WS; So Y
J Cancer Res Clin Oncol; 2014 Jan; 140(1):89-98. PubMed ID: 24194352
[TBL] [Abstract][Full Text] [Related]
5. Volumetric PET parameters can predict overall survival in advanced lung adenocarcinoma.
Yanarateş A; Yazici B
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):3-8. PubMed ID: 31818695
[TBL] [Abstract][Full Text] [Related]
6. Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.
Ko KH; Hsu HH; Huang TW; Gao HW; Shen DH; Chang WC; Hsu YC; Chang TH; Chu CM; Ho CL; Chang H
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1889-97. PubMed ID: 24852187
[TBL] [Abstract][Full Text] [Related]
7. [Semiquantitative parameters of
Liao XH; Wang RF; Liu M; Chen XQ; Xiong Y; Nong L; Yin L; Zhang BY; DU YJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 53(2):246-254. PubMed ID: 33879893
[TBL] [Abstract][Full Text] [Related]
8. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma.
Huang CT; Yen RF; Cheng MF; Hsu YC; Wei PF; Tsai YJ; Tsai MF; Shih JY; Yang CH; Yang PC
Med Oncol; 2010 Mar; 27(1):9-15. PubMed ID: 19130320
[TBL] [Abstract][Full Text] [Related]
9. Correlation between EGFR mutation status and F
Zhu L; Yin G; Chen W; Li X; Yu X; Zhu X; Jiang W; Jia C; Chen P; Zhang Y; Lu D; Yu L; Li X; Xu W
Thorac Cancer; 2019 Apr; 10(4):659-664. PubMed ID: 30776196
[TBL] [Abstract][Full Text] [Related]
10. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
Ho KC; Fang YD; Chung HW; Liu YC; Chang JW; Hou MM; Yang CT; Cheng NM; Su TP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2155-2165. PubMed ID: 27260520
[TBL] [Abstract][Full Text] [Related]
11. Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor mutation.
Lee EY; Khong PL; Lee VH; Qian W; Yu X; Wong MP
Clin Nucl Med; 2015 Mar; 40(3):e190-5. PubMed ID: 25608155
[TBL] [Abstract][Full Text] [Related]
12. [Value of (18)F-FDG PET-CT imaging to predict epidermal growth factor receptor mutations in patients with lung squamous cell carcinoma].
Zhao CY; Deng XY; Wang HS; Cao GP; Ding JN; Ding CY
Zhonghua Zhong Liu Za Zhi; 2021 Jul; 43(7):795-800. PubMed ID: 34289575
[No Abstract] [Full Text] [Related]
13. Relation of EGFR Mutation Status to Metabolic Activity in Localized Lung Adenocarcinoma and Its Influence on the Use of FDG PET/CT Parameters in Prognosis.
Kim YI; Paeng JC; Park YS; Cheon GJ; Lee DS; Chung JK; Kang KW
AJR Am J Roentgenol; 2018 Jun; 210(6):1346-1351. PubMed ID: 29547059
[TBL] [Abstract][Full Text] [Related]
14. Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma.
Takamochi K; Mogushi K; Kawaji H; Imashimizu K; Fukui M; Oh S; Itoh M; Hayashizaki Y; Ko W; Akeboshi M; Suzuki K
PLoS One; 2017; 12(4):e0175622. PubMed ID: 28422979
[TBL] [Abstract][Full Text] [Related]
15. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.
Shady W; Kishore S; Gavane S; Do RK; Osborne JR; Ulaner GA; Gonen M; Ziv E; Boas FE; Sofocleous CT
Eur J Radiol; 2016 Jun; 85(6):1224-31. PubMed ID: 27161074
[TBL] [Abstract][Full Text] [Related]
16. The value of dynamic FDG PET/CT in the differential diagnosis of lung cancer and predicting EGFR mutations.
Wumener X; Zhang Y; Zang Z; Du F; Ye X; Zhang M; Liu M; Zhao J; Sun T; Liang Y
BMC Pulm Med; 2024 May; 24(1):227. PubMed ID: 38730287
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
18. Total lesion glycolysis by 18F-FDG PET/CT is independent prognostic factor in patients with advanced non-small cell lung cancer.
Yıldırım F; Yurdakul AS; Özkaya S; Akdemir ÜÖ; Öztürk C
Clin Respir J; 2017 Sep; 11(5):602-611. PubMed ID: 26434685
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
[TBL] [Abstract][Full Text] [Related]
20. Contribution of ¹⁸Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma.
Kanmaz ZD; Aras G; Tuncay E; Bahadır A; Kocatürk C; Yaşar ZA; Öz B; Özkurt CÜ; Gündoğan C; Çermik TF
Cancer Biomark; 2016; 16(3):489-98. PubMed ID: 27062706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
